| Risk SNP-mediated promoter-enhancer switching drives prostate cancer through lncRNA PCAT19 JT Hua, M Ahmed, H Guo, Y Zhang, S Chen, F Soares, J Lu, S Zhou, ... Cell 174 (3), 564-575. e18, 2018 | 312 | 2018 |
| GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer Q Wu, W Ba-Alawi, G Deblois, J Cruickshank, S Duan, E Lima-Fernandes, ... Nature communications 11 (1), 4205, 2020 | 215 | 2020 |
| TMPRSS2–ERG fusion co-opts master transcription factors and activates NOTCH signaling in primary prostate cancer KJ Kron*, A Murison*, S Zhou, V Huang, TN Yamaguchi, YJ Shiah, ... Nature genetics 49 (9), 1336, 2017 | 188 | 2017 |
| A chemical toolbox for the study of bromodomains and epigenetic signaling Q Wu, D Heidenreich, S Zhou, S Ackloo, A Krämer, K Nakka, ... Nature communications 10 (1), 1915, 2019 | 135 | 2019 |
| Pioneer of prostate cancer: past, present and the future of FOXA1 M Teng*, S Zhou*, C Cai, M Lupien, HH He Protein & Cell, 1-10, 2020 | 121 | 2020 |
| Emergence of the noncoding cancer genome: a target of genetic and epigenetic alterations S Zhou, AE Treloar, M Lupien Cancer discovery 6 (11), 1215-1229, 2016 | 97 | 2016 |
| Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer S Zhou, JR Hawley, F Soares, G Grillo, M Teng, SA Madani Tonekaboni, ... Nature communications 11 (1), 441, 2020 | 77 | 2020 |
| The transition from quiescent to activated states in human hematopoietic stem cells is governed by dynamic 3D genome reorganization N Takayama, A Murison, S Takayanagi, C Arlidge, S Zhou, L Garcia-Prat, ... Cell stem cell 28 (3), 488-501. e10, 2021 | 72 | 2021 |
| Cistrome Partitioning Reveals Convergence of Somatic Mutations and Risk Variants on Master Transcription Regulators in Primary Prostate Tumors P Mazrooei*, KJ Kron*, Y Zhu‡, S Zhou‡, G Grillo, T Mehdi, M Ahmed, ... Cancer cell 36 (6), 674-689. e6, 2019 | 64 | 2019 |
| CRISPRi screens reveal a DNA methylation-mediated 3D genome dependent causal mechanism in prostate cancer M Ahmed, F Soares, JH Xia, Y Yang, J Li, H Guo, P Su, Y Tian, HJ Lee, ... Nature communications 12 (1), 1781, 2021 | 43 | 2021 |
| Transposable elements are co-opted as oncogenic regulatory elements by lineage-specific transcription factors in prostate cancer G Grillo, T Keshavarzian, S Linder, C Arlidge, L Mout, A Nand, M Teng, ... Cancer discovery 13 (11), 2470-2487, 2023 | 17 | 2023 |
| Reorganization of the 3D Genome Pinpoints Noncoding Drivers of Primary Prostate Tumors JR Hawley*, S Zhou*, C Arlidge, G Grillo, KJ Kron, R Hugh-White, ... Cancer Research 81 (23), 5833-5848, 2021 | 16* | 2021 |
| Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer S Cameron, G Deblois, JR Hawley, A Qamra, S Zhou, SAM Tonekaboni, ... Oncogene 42 (21), 1693-1703, 2023 | 15 | 2023 |
| Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer SG Zhao*, M Bootsma*, S Zhou*, R Shrestha, T Moreno-Rodriguez, ... Nature Genetics, 1-12, 2024 | 6 | 2024 |
| An atlas of accessible chromatin in advanced prostate cancer reveals the epigenetic evolution during tumor progression R Shrestha, LN Chesner, M Zhang, S Zhou, A Foye, A Lundberg, ... Cancer Research 84 (18), 3086-3100, 2024 | 3 | 2024 |
| Development of AB-2100, an autologous integrated circuit T (ICT) cell therapy targeting CA9 intended for the treatment of ccRCC. M Landon, I Scarfo, M Chew, R Sudhakah, M Nguyen, S Mohanty, J Chen, ... Journal of Clinical Oncology 42 (4_suppl), 472-472, 2024 | 1 | 2024 |
| Abstract B037: AB-2100, a PSMA-inducible CA9-specific CAR T cell product intended for the treatment of ccRCC provides long-term tumor responses in preclinical mouse model S Mohanty, J Chen, A Gomez, A Boroughs, I Scarfo, L Lim, K Dang, ... Cancer Immunology Research 12 (10_Supplement), B037-B037, 2024 | | 2024 |
| Abstract LB196: An atlas of accessible chromatin in advanced prostate cancer R Shrestha, LN Chesner, M Zhang, S Zhou, A Foye, A Lundberg, ... Cancer Research 84 (7_Supplement), LB196-LB196, 2024 | | 2024 |
| AB-2100, a PSMA-inducible CA9-specific CAR T cell product for the treatment of ccRCC provides long-term tumor responses in preclinical mouse model S Mohanty, J Chen, A Gomez, A Boroughs, I Scarfo, L Lim, K Dang, ... Cancer Research 84 (6_Supplement), 38-38, 2024 | | 2024 |
| Systems targeting psma and ca9 A Boroughs, L Gray-Rupp, SA Williams, ZJ Zhou, M Drever, D Nguyen, ... US Patent US20240342284A1, 2024 | | 2024 |